Davis Polk advised Royalty Pharma plc and the selling shareholders on the offering. Royalty Pharma executed its $728 million secondary offering of 17,343,037 of its Class…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Ambrogio Visconti
…
This content is for Standard 1 Year members only. LoginJoin Now